AAV-Delivered RNA Targeting Therapy for Neurodegeneration

Overview

Executive Summary

Overview

Executive Summary

Target: Disease-driving RNA transcripts via AAV-mediated delivery Approach: AAV vectors carrying RNA-targeting payloads (ASO, RNAi, RNA aptamers) to reduce expression of toxic proteins Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia Score: 77/100

Mechanism of Action

AAV Delivery Platform

Recombinant AAV vectors provide non-integrating, long-term expression of RNA-targeting payloads in the CNS.[@highland2024] Recent advances in capsid engineering have improved CNS tropism and reduced immunogenicity.[@klein2023]

Key advantages:

• Long-term expression (years) from single administration
• Broad neuronal and glial transduction
• Proven clinical safety in other CNS indications (SMA, CLN2)[@sah2023]
• Ability to target specific brain regions via stereotactic injection

RNA-Targeting Modalities

Therapeutic Rationale

In neurodegeneration, specific genetic drivers can be targeted to reduce toxic protein expression:[@finkel2024]

• Alzheimer's: [APP](/entities/app-protein), [PSEN1](/entities/psen1), [PSEN2](/entities/psen2) (reduce [Aβ](/proteins/amyloid-beta) production)
• Parkinson's: SNCA (reduce alpha-synuclein), LRRK2 (reduce mutant kinase)
• ALS/FTD: [C9orf72](/entities/c9orf72) (reduce toxic DPRs), SOD1, FUS, TARDBP
• FTD: MAPT (reduce tau), GRN (increase progranulin)

Scoring (10-Dimension Rubric)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | First-in-class AAV+RNA targeting combination; only now becoming technically feasible |
| Mechanistic Rationale | 9 | Strong genetic validation; reducing toxic protein levels is well-established therapeutic strategy |
| Addresses Root Cause | 8 | Directly reduces expression of disease-driving proteins |
| Delivery Feasibility | 6 | AAV delivery proven but requires stereotactic injection; CNS selectivity still developing |
| Safety Plausibility | 7 | AAV platform has good safety profile; off-target effects of RNA targeting need monitoring |
| Combinability | 8 | Combines well with small molecule approaches, other gene therapies |
| Biomarker Availability | 7 | Target protein levels in CSF; sequencing to confirm on-target reduction |
| De-risking Path | 7 | Can use mouse models; iPSC-derived [neurons](/entities/neurons) for human validation |
| Multi-disease Potential | 9 | Platform applicable across AD, PD, ALS, FTD with minimal modification |
| Patient Impact | 8 | Potentially disease-modifying; single administration could provide years of benefit |

Total: 77/100

Target Selection by Disease

Alzheimer's Disease

| Target | Rationale | Approach |
|--------|-----------|----------|
| APP | Direct cause of Aβ production | ASO to reduce APP translation |
| PSEN1/2 | [Gamma-secretase](/entities/gamma-secretase) catalytic subunit | ASO to reduce mutant expression |
| APOE4 | Major genetic risk factor | RNA aptamer to block ApoE4 aggregation |

Parkinson's Disease

| Target | Rationale | Approach |
|--------|-----------|----------|
| SNCA | [Alpha-synuclein](/proteins/alpha-synuclein) multiplication is causal | RNAi to reduce expression |
| LRRK2 | Most common genetic cause (G2019S) | ASO to reduce mutant kinase |
| GBA1 | Strong genetic risk factor | Increase expression via UTR modulation |

ALS/FTD

| Target | Rationale | Approach |
|--------|-----------|----------|
| C9orf72 | 40% familial ALS, 25% FTD | ASO to reduce toxic DPRs |
| SOD1 | 20% familial ALS | RNAi to reduce mutant protein |
| FUS | 5% familial ALS | ASO to reduce mutant expression |
| GRN | Causes progranulin deficiency in FTD | Increase expression via RNA targeting |

Frontotemporal Dementia

| Target | Rationale | Approach |
|--------|-----------|----------|
| MAPT | Tau mutations cause FTD | ASO to reduce tau isoforms |
| TMEM106B | Major risk factor | Modulate expression |
| GRN | Progranulin haploinsufficiency | Increase expression |

Development Pathway

Phase 1: Target Validation (Months 1-18)

• Validate target knockdown in patient-derived iPSC neurons
• Confirm phenotypic improvement in disease models
• Optimize AAV serotype for target brain region
• Establish PK/PD relationship in non-human primates

Phase 2: IND-Enabling Studies (Months 12-30)

• GMP vector production and release testing
• IND-enabling toxicology in rodents and NHPs
• Develop CSF biomarker assay for target engagement
• Design clinical dosing regimen

Phase 3: Clinical Development (Months 24-48)

• Phase 1 safety in small patient cohort[@stoops2023]
• Dose-escalation with biomarker readouts
• Registrational trial design for specific indication
• Companion diagnostic development

Combination Therapy Opportunities

Synergistic Targets

Preclinical Combination Data

• AAV-ASO + TFEB agonist: Synergistic reduction of protein aggregates in models[@keeler2022]
• RNAi targeting + antibody: Enhanced clearance via dual mechanism

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Implementation Roadmap

Phase 1: Target Validation ($2.5-4M, Months 1-18)

• Vector engineering and screening: $800K
• In vitro validation (iPSC neurons): $600K
• In vivo proof-of-concept (mouse models): $700K
• Pharmacokinetics/biodistribution: $400K
• IND-enabling studies start: $500K
• Milestone: Demonstrate >70% target knock-down in relevant models

Phase 2: IND-Enabling ($5-8M, Months 12-30)

• GMP manufacturing: $2M
• GLP toxicology (rodent + NHP): $2.5M
• Biomarker assay development: $500K
• Regulatory interactions: $300K
• Clinical protocol finalization: $700K
• Milestone: IND clearance

Phase 3: Clinical Development ($25-40M, Months 24-54)

• Phase 1 trial: $5-8M
• Phase 2 trial: $10-15M
• Phase 3 trial: $10-17M
• Milestone: Regulatory approval or partnership exit

Total Program Cost: $33-52M over 54 months

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Immunogenicity against AAV | Medium | High | Pre-screen for neutralizing antibodies; use novel capsids |
| Off-target RNA effects | Low | Medium | Extensive bioinformatic analysis; chemical modifications |
| Delivery to non-target regions | Medium | Medium | Advanced imaging for distribution; promoter optimization |
| Regulatory complexity | Medium | Medium | Early FDA engagement; rare disease pathway if applicable |

Go/No-Go Decision Points

Cross-Linking

• [TREM2](/proteins/trem2) - Related microglial target
• C9orf72 - Target for ALS/FTD
• SNCA - Target for PD
• LRRK2 - Target for PD
• APP - Target for AD
• MAPT - Target for FTD
• GRN - Target for FTD
• SOD1 - Target for ALS
• Alpha-Synuclein - Pathogenic protein in PD
• [Tau Protein](/proteins/tau) - Pathogenic protein in AD/FTD
• AAV Vector - Delivery platform

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References